Stereotaxis (STXS) Projected to Post Quarterly Earnings on Tuesday

Stereotaxis (NYSEAMERICAN:STXS) is expected to release its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect Stereotaxis to post earnings of ($0.05) per share and revenue of $8.62 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Stereotaxis (NYSEAMERICAN:STXS) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). The business had revenue of $8.64 million during the quarter, compared to analysts’ expectations of $9.24 million. Stereotaxis had a negative return on equity of 291.99% and a negative net margin of 66.85%. On average, analysts expect Stereotaxis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Stereotaxis Price Performance

NYSEAMERICAN:STXS traded up $0.06 during trading hours on Tuesday, reaching $1.96. 70,041 shares of the company were exchanged, compared to its average volume of 481,004. The company has a market capitalization of $190.57 million, a P/E ratio of -7.78 and a beta of 1.34. The business has a 50 day moving average of $1.95 and a 200 day moving average of $2.30. Stereotaxis has a 1-year low of $1.74 and a 1-year high of $3.59.

Institutional Investors Weigh In On Stereotaxis

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bridgeway Capital Management LLC grew its stake in Stereotaxis by 56.6% during the fourth quarter. Bridgeway Capital Management LLC now owns 221,475 shares of the company’s stock worth $509,000 after buying an additional 80,075 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its position in shares of Stereotaxis by 47.0% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 17,801 shares of the company’s stock worth $41,000 after acquiring an additional 5,692 shares in the last quarter. Abel Hall LLC bought a new position in Stereotaxis in the fourth quarter valued at approximately $53,000. Equitable Holdings Inc. acquired a new position in Stereotaxis during the fourth quarter valued at approximately $46,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in Stereotaxis by 12.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 95,221 shares of the company’s stock worth $220,000 after purchasing an additional 10,235 shares during the last quarter. Institutional investors own 45.35% of the company’s stock.

About Stereotaxis

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.